Skip to main content

Siklos Disease Interactions

There are 5 disease interactions with Siklos (hydroxyurea).

Major

Hydroxyurea (applies to Siklos) myelosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever

The use of hydroxyurea is contraindicated in patients with marked myelosuppression. Hydroxyurea induces myelosuppression, primarily leukopenia. Thrombocytopenia and anemia occur less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Hydroxyurea should not be administered if the white blood cell count falls below 2500/mm3 and/or the platelet count falls below 100,000/mm3, or in the presence of severe anemia.

References

  1. "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb PROD (2001):
Major

Hydroxyurea (applies to Siklos) renal dysfunction

Major Potential Hazard, High plausibility.

Hydroxyurea is primarily eliminated by the kidney. Approximately 80% of urea is excreted in the urine as unchanged drug or urea. Patients with marked renal impairment (CrCl < 60 mL/min or ESRD) may be at increased risk of toxicity associated with administration of hydroxyurea. Therapy with hydroxyurea should be administered cautiously to patients with compromised renal function.

References

  1. "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb PROD (2001):
Moderate

Hydroxyurea (applies to Siklos) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

There are no data supporting specific guidance for hydroxyurea dosage adjustment in patients with hepatic impairment. Caution and close monitoring is advised in these patients.

References

  1. "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb PROD (2001):
Moderate

Hydroxyurea (applies to Siklos) seizure disorders

Moderate Potential Hazard, Low plausibility. Applicable conditions: Seizures

Seizures have been noted very rarely during hydroxyurea therapy. Therapy with hydroxyurea should be administered cautiously in patients with seizure disorders.

References

  1. "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb PROD (2001):
Minor

Hydroxyurea (applies to Siklos) neurologic disorders

Minor Potential Hazard, Low plausibility. Applicable conditions: Psychosis

Neurological symptoms such as disorientation or hallucinations have been reported very rarely during hydroxyurea therapy. Therapy with hydroxyurea should be administered cautiously to patients with or predisposed to neurological disorders.

References

  1. "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb PROD (2001):

Siklos drug interactions

There are 274 drug interactions with Siklos (hydroxyurea).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.